CBSA has serious concerns about the Colorado Prescription Drug Affordability Board’s inconsistent approach to the preliminary data review process for drugs under affordability review in the first cohort. CBSA submitted a letter on Friday to Board members and staff expressing those concerns.
In addition, CBSA expressed concerns about the potential imposition of upper payment limits through a letter submitted to the PDAB in advance of the October 27th meeting and public comment by CBSA’s Vice President & Counsel for Policy + Advocacy during the meeting.
The PDAB’s October 27th Meeting
The Colorado Prescription Drug Affordability Board (PDAB or Board) has selected five drugs for an affordability review and will be determining whether to deem them “unaffordable” for Colorado patients. If the PDAB does deem them unaffordable, the PDAB will then determine whether to set an upper payment…
Click here to view original post
